Aptevo Therapeutics Inc.
APVOHealthcare|Biotechnology|US
$1.24
-0.03 (-2.36%)
DCF Value
$5119.24
Tangible Book / Share
$5.05
Cash / Share
$8.19
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06634394 APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | Acute Myeloid Leukemia (AML) | P1 | Recruiting | 39 | Open-label | APVO436, Venetoclax, Azacitidine |
| NCT05934539 ALG.APV-527 First-in-human Study | Solid Tumor | P1P2 | Unknown | 56 | Open-label | ALG.APV-527 |
| NCT01188681 Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia (CLL) | P1P2 | Completed | 79 | RCT, Open-label | TRU-016 and bendamustine, Bendamustine, 15 mg/kg TRU-016 and bendamustine, 20 mg/kg TRU-016 and bendamustine |
| NCT04973618 Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML | AML | P1 | Withdrawn | — | Open-label | APVO436 |
| NCT03647800 Study of APVO436 in Patients With AML or MDS | AML, MDS | P1 | Unknown | 136 | Open-label | APVO436 |
| NCT00614042 Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) | P1 | Completed | 96 | Open-label | TRU-016 (anti-CD37 protein therapeutic) |
| NCT02262910 Study of ES414 in Metastatic Castration-Resistant Prostate Cancer | Prostate Cancer | P1 | Completed | 35 | Open-label | ES414 |
| NCT01317901 A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma | B-cell Small Lymphocytic Lymphoma Recurrent | P1 | Completed | 12 | Open-label | TRU-016, Bendamustine, Rituximab |
| NCT03768219 Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis | Psoriasis, Ulcerative Colitis | P1 | Terminated | 85 | RCT, Double-blind | APVO210, Placebo |
| NCT01644253 Phase 1b Safety and Efficacy Study of TRU-016 | Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma | P1 | Terminated | 87 | Open-label | 20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab, TRU-016 6-20 mg/kg + idelalisib + rituximab, TRU-016 10-20 mg/kg + ibrutinib, TRU-016 10-20 mg/kg + bendamustine |